Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an ...

Sexually transmitted infections (STIs) have become increasingly common worldwide and now represent a major public health concern, particularly among young people aged 15 to 24 years. Globally, more ...

Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement ...

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

We go to school, study further, then learn new things in our chosen careers. But no matter how much knowledge we acquire, ...

For more than a decade, doctors and researchers have announced that a handful of people around the world have been cured of ...